Abstract:Background: Haematological patients with severe thrombocytopenia and high thrombotic risk face challenges related to balancing bleeding and thrombosis risks. This study investigated factors associated with bleeding and thrombosis in high-risk haematological oncology patients with severe thrombocytopenia not receiving anticoagulant therapy and characterized their clinical features when both events occurred. Methods: A total of 446 haematological oncology patients with Caprini scores ≥ 5 were included from July 2022 to June 2023 at Mianyang City Central Hospital. Those not receiving prophylactic anticoagulants due to an admission platelet count < 50 × 109/L were studied. Patients were categorized into bleeding/nonbleeding and thrombotic/nonthrombotic groups on the basis of hospital course. Relevant clinical data were collected, and univariate/multivariate logistic regression was used to analyse the influencing factors. The platelet count at admission was assessed via ROC curves for thrombosis prediction. Results: In the bleeding group, higher proportions of patients with leukaemia, myeloid tumours, lung infections, and a central venous catheter (CVC) with two lumens were observed, along with shorter catheter durations, lower initial and minimum platelet counts during hospitalization, and prolonged plasminogen times (all P < 0.05). The thrombotic group had a greater thrombosis history, initial platelet count, use of two venous catheter lumens, parenteral nutrition, sedation, and autologous haematopoietic stem cell transplantation (Auto-HSCT), with a lower leukaemia proportion (P < 0.05). Logistic regression identified lymphoma type and minimum platelet count as bleeding protective factors and the Charlson Comorbidity Index (CCI) score as an independent risk factor. Thrombosis history, two venous catheter lumens, and sedation were risk factors for thrombosis. The median platelet count was lower at bleeding and thrombosis than at admission (P = 0.007). The platelet count at admission had predictive value for thrombosis, especially severe thrombocytopenia, with an AUC of 0.735 (95% CI 0.613-0.858, P = 0.003) and a cut-off value of 42.5 × 109/L. Conclusions: For haematological neoplasm patients with a high risk of venous thromboembolism (VTE), severe thrombocytopenia and high CCI scores, risk prevention and control of bleeding take precedence over thrombosis prophylaxis. Prophylactic anticoagulation is still recommended for patients with lymphoma assessed at high risk for VTE and with platelet counts of at least 42.5 × 109/L.

Managing Patients With Concurrent High Risk for Bleeding and Thromboembolic Events

Best Strategies to Minimize Severe Bleeding Risk

Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions

The Management and Antithrombotic Strategies of Patients with Coronary Artery Disease and High Bleeding Risk

Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

Prevention of Gastrointestinal Events in Patients on Antithrombotic Therapy in the Peri‐endoscopy Period: Review of New Evidence and Recommendations from Recent Guidelines

The Challenging Scenarios of Life-Threatening Bleeding and Unplanned Invasive Procedures

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions

Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease

Antithrombotic therapy in high-risk patients after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events

Management of bleeding in patients on direct oral anticoagulants in emergency department: where we are and where we are going

Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparin

Clinical analysis of bleeding and thrombotic events in haematological-oncology patients with severe thrombocytopenia and a high risk of thrombosis

[Is Low-Dose Anticoagulation a Therapeutic Option for Patients at High Risk of Bleeding with High-Risk Pulmonary Thromboembolism].

Individualising Antithrombotic Strategies for Acute and Chronic Coronary Syndromes

How to undertake procedures while on antiplatelet agents: a hematologist's view

Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum

Challenging anticoagulation therapy for multiple primary malignant tumors combined with thrombosis: A case report and review of literature

Contribution of ESC DAPT guideline-endorsed high thrombotic risk features to long-term clinical outcomes among patients with and without high bleeding risk after PCI

Management of Bleeding Diathesis in Elective and Orthopaedic Trauma: A Review